Clinical Research Directory
Browse clinical research sites, groups, and studies.
Inositol in Letrozol Resistant PCOS Women
Sponsor: Kafrelsheikh University
Summary
Polycystic ovary syndrome (PCOS),is a complex neuro-endocrine disorder affecting approximately 5% to 10% of women in reproductive age.Inositols are considered insulin sensitizers, as they modulate the members of insulin signaling pathways.Thiss study compares between the effect of inositol and metformin in letrozol resistant PCOS women.
Official title: Efficacy of Inositol in Managing Subfertility in Letrozole-resistant Polycystic Ovary Syndrome Women
Key Details
Gender
FEMALE
Age Range
20 Years - 38 Years
Study Type
INTERVENTIONAL
Enrollment
136
Start Date
2024-04-10
Completion Date
2026-07-11
Last Updated
2026-09-29
Healthy Volunteers
No
Conditions
Interventions
Myoinositol
Myo-inositol 2 g orally twice daily (4 g/day) for 8 weeks as metabolic priming, followed by letrozole 7.5 mg/day orally on cycle days 3-7 for three consecutive cycles. Folic acid 400 µg/day is administered throughout the study.
Metformin
Metformin initiated at 500 mg orally once daily and increased by 500 mg weekly as tolerated to a target dose of 1500 mg/day, administered for 8 weeks as metabolic priming, followed by letrozole 7.5 mg/day orally on cycle days 3-7 for three consecutive cycles. Folic acid 400 µg/day is administered throughout the study.
Locations (1)
Kafrelshiekh university hospital
Cairo, Egypt